Atlas Trials

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Clinical trial NCT04933825 · UNKNOWN

Trial details

NCT number
NCT04933825
Sponsor
EdiGene (GuangZhou) Inc.
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Relapsed or Refractory B-cell Malignancy(NHL/ALL)
Start date
2021-07-20
Primary completion
2024-09-30
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.